Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors
about
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirusCircular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue.Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectorsAdeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expressionAdeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1Gene Therapy for Cardiovascular DiseaseIn vivo detection of gene expression in liver by 31P nuclear magnetic resonance spectroscopy employing creatine kinase as a marker gene.Genetic fate of recombinant adeno-associated virus vector genomes in muscleDirected evolution of adeno-associated virus yields enhanced gene delivery vectors.Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferAdeno-associated virus vectors and hematologyAdeno-associated viral vectors for gene transfer and gene therapy.A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.Strategy of liver-directed gene therapy: present status and future prospects.Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin.Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectorsCharacterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their eliminationSuccessful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposureImpaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts.Kinetics of recombinant adeno-associated virus-mediated gene transfer.Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver.BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver.Repeated delivery of adeno-associated virus vectors to the rabbit airway.Gene therapy for hemophilia.Immune responses to adenovirus and adeno-associated virus in humans.Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo.Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivoFlupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons.Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice.High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapyAdeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo.Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignanciesGene therapy for haemophilia.Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.Intracellular transport of recombinant adeno-associated virus vectors.Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector productionHeat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.Adeno-associated virus vectors: potential applications for cancer gene therapy.
P2860
Q24523073-602E6F47-1B71-431C-8B2A-B32BFC7678F1Q24523651-EE50EBE6-0A19-413C-8E51-0D3529682A99Q24529153-391DC25A-683B-4C3E-9BEE-B64547EDA0A8Q24529167-1AA8A507-F458-4514-9AD4-CCD8DA45C088Q24634560-D14E4687-0A1F-40F1-B514-2EBD8FEBC559Q24791063-65005E2F-3E13-40F1-A7A2-51364FA6D0D8Q30647046-569FFB49-5877-46BD-8A6F-4B3F43CE8F9CQ33186207-86237757-7289-41E6-94FF-9FE9BA5E28F1Q33232270-EAC48E4F-6D11-4D43-A0EF-08CF12F7460FQ33296224-7E07EA03-81DE-48E7-81A5-D6FC8958A727Q33695816-4526806F-DB12-48E2-A6BD-002954C684A6Q33701559-DC90DB73-25C2-4580-9A65-9078CB68C264Q33713730-48E1D45C-10CA-4E0B-A23A-82CAC613F3D8Q33718826-A63392FC-AB40-4BA3-AD47-BC82C022E9B8Q33735882-9E917351-288F-47E1-AF55-BE2AE57072A4Q33783728-EF8965F6-6DAD-40CD-814F-4634EB0D20AFQ33784934-5E995536-425C-4B42-BDB7-58961AD8C443Q33786029-E34FEC22-B06F-4015-8931-1B1B72240353Q33796712-C3CDFC0A-1057-4E07-BBB7-96B0EBB0174EQ33802149-6D16255F-4F44-4618-8E9F-EA3EE505A5FCQ33815070-A4DFA38A-0662-4BC9-B65D-D6B49D5D014FQ33822204-0AB9D6D7-02C9-4DEA-B10B-6BCAE997BC1DQ33823405-023B02FD-0DF3-4137-8A37-B5A56390FC08Q33838660-82F69631-3DA7-47A0-B70C-AB8A08437EC7Q33874473-06620069-548B-4771-B4D7-C6397E7FFDB1Q33919915-50D11BED-0A05-4E38-8EC9-F645A78D3D8AQ34070164-ACA5C708-9EF7-4B99-9BDB-5A54EE4829A9Q34121060-CA842328-8431-45D7-835A-298CD969F7F3Q34226663-077705F8-9804-4755-9743-0EC66B742DB9Q34329364-40934E53-BCDD-4437-800F-5DFC89665805Q34472029-397CD36B-DD13-44CD-86C6-772C44FF7445Q34482357-E1DB0116-B0D9-4F84-B053-6B08532C8033Q34530130-D6EDE01A-352C-4102-A17F-04A837FD2B08Q34938807-AEC04B50-A7BF-4545-AC91-E1D9C1AA7F4AQ35734826-3C8B3262-5A28-4529-8546-A9A8A410A221Q35889903-73943765-3FCB-424B-A00B-ABA7B0BE5E87Q35891981-9C5EB30B-A0A3-4D1B-B32F-E4D2266584A9Q36004744-F37CC11A-22A8-4F1A-8DBB-B91BA7CD3C0AQ36009041-84060A1B-6DB5-426C-941B-312A9CCD9FC0Q36165834-A18AA126-7780-4E7C-87E4-76B0ACA87139
P2860
Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Persistent expression of human ...... adeno-associated virus vectors
@ast
Persistent expression of human ...... adeno-associated virus vectors
@en
Persistent expression of human ...... adeno-associated virus vectors
@nl
type
label
Persistent expression of human ...... adeno-associated virus vectors
@ast
Persistent expression of human ...... adeno-associated virus vectors
@en
Persistent expression of human ...... adeno-associated virus vectors
@nl
prefLabel
Persistent expression of human ...... adeno-associated virus vectors
@ast
Persistent expression of human ...... adeno-associated virus vectors
@en
Persistent expression of human ...... adeno-associated virus vectors
@nl
P2093
P2860
P356
P1476
Persistent expression of human ...... adeno-associated virus vectors
@en
P2093
A D Miller
C L Halbert
D D Koeberl
D W Russell
I E Alexander
P2860
P304
P356
10.1073/PNAS.94.4.1426
P407
P577
1997-02-18T00:00:00Z